➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Colorcon
Merck
Johnson and Johnson
Medtronic

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIMOLOL MALEATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Timolol Maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00108017 Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2005-04-01 This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
NCT00273442 Assessing Cosopt Switch Patients Completed Pharmaceutical Research Network Phase 4 2005-11-01 To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
NCT00273481 Cosopt Versus Xalacom Completed Pharmaceutical Research Network Phase 4 2005-09-01 To compare the intraocular pressure efficacy and safety of the DTFC given twice daily versus the LTFC given once every morning following a run-in period with timolol maleate given twice daily.
NCT00330577 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed Aristotle University Of Thessaloniki Phase 4 2006-04-01 The purpose of this study is to compare the short-term mean 24-hour intraocular pressure control, 24-hour blood pressure effect and safety of Latanoprost/Timolol fixed combination given once in the evening with placebo once in the morning versus timolol maleate 0.5% given twice daily in patients with ocular hypertension and primary open-angle glaucoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Timolol Maleate

Condition Name

Condition Name for Timolol Maleate
Intervention Trials
Ocular Hypertension 34
Glaucoma 18
Open-Angle Glaucoma 15
Hemangioma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Timolol Maleate
Intervention Trials
Glaucoma 40
Ocular Hypertension 39
Glaucoma, Open-Angle 34
Hypertension 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Timolol Maleate

Trials by Country

Trials by Country for Timolol Maleate
Location Trials
United States 104
Spain 6
Germany 4
Canada 4
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Timolol Maleate
Location Trials
California 11
New York 7
Georgia 6
New Jersey 6
Tennessee 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Timolol Maleate

Clinical Trial Phase

Clinical Trial Phase for Timolol Maleate
Clinical Trial Phase Trials
Phase 4 22
Phase 3 15
Phase 2 11
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Timolol Maleate
Clinical Trial Phase Trials
Completed 35
Recruiting 13
Withdrawn 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Timolol Maleate

Sponsor Name

Sponsor Name for Timolol Maleate
Sponsor Trials
Alcon Research 8
Allergan 5
Aerie Pharmaceuticals 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Timolol Maleate
Sponsor Trials
Industry 43
Other 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
McKinsey
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.